Staar Surgical (STAA) Cash & Equivalents (2010 - 2026)

Staar Surgical (STAA) has 17 years of Cash & Equivalents data on file, last reported at $131.9 million in Q2 2026.

• Quarterly Cash & Equivalents fell 23.83% year-over-year to $131.9 million in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $131.9 million (down 23.83% YoY) and the FY2026 annual result came in at $153.2 million, up 6.24% from the prior year.
• Cash & Equivalents slipped to $131.9 million in Q2 2026, from $153.2 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $224.0 million in Q1 2024 to a low of $86.5 million in Q4 2022.
• A 5-year average of $154.9 million and a median of $164.0 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents slumped 56.7% — and 2024, when it soared 149.0%.
• Tracing STAA's Cash & Equivalents over 5 years: stood at $86.5 million in 2022, then surged by 111.65% to $183.0 million in 2023, then slipped by 21.24% to $144.2 million in 2024, then increased by 22.19% to $176.2 million in 2025, then fell by 25.14% to $131.9 million in 2026.
• The last three Cash & Equivalents figures came in at $131.9 million (Q2 2026), $153.2 million (Q1 2026), and $176.2 million (Q3 2025), per Business Quant data.